Related references
Note: Only part of the references are listed.Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis
Motoaki Hoshino et al.
Modern Rheumatology (2014)
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Fabien B. Vincent et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Pauline A. van Schouwenburg et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
A. Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
Charlotte L. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway
Saba Alzabin et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
Sophie Martin Du Pan et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to Immunogenicity
Charlotte L. Krieckaert et al.
ARTHRITIS AND RHEUMATISM (2012)
Etanercept Concentration in Patients with Rheumatoid Arthritis and Its Potential Influence on Treatment Decisions: A Pilot Study
Claire Immediato Daien et al.
JOURNAL OF RHEUMATOLOGY (2012)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Differential effect of drug interference in immunogenicity assays
Margreet H. Hart et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
Wietske Kievit et al.
RHEUMATOLOGY (2011)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Dora Pascual-Salcedo et al.
RHEUMATOLOGY (2011)
Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study
Jean-Camille Meric et al.
THERAPEUTIC DRUG MONITORING (2011)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry
Merete Lund Hetland et al.
ARTHRITIS AND RHEUMATISM (2010)
Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases
Nadia Emi Aikawa et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA
Alfons A. den Broeder et al.
RHEUMATOLOGY (2010)
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
Charlotte Louise Maria Krieckaert et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
M. K. de Vries et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Dealing with immunogenicity of biologicals: assessment and clinical relevance
Gerrit J. Wolbink et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week - Results of a multicenter, randomized, double-blind, active drug-controlled study
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2008)
Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement
Lucien Aarden et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M. Svenson et al.
RHEUMATOLOGY (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
C. J. van der Laken et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Joint inflammation and cytokine inhibition in rheumatoid arthritis
C Christodoulou et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)
J Ledingham et al.
RHEUMATOLOGY (2005)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis.
EHS Choy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)